賴 嘉鎮

Medicine & Life Sciences

1. Cohort Studies 67%
2. Databases 52%
3. Sodium-Glucose Transport Proteins 44%
4. Antipsychotic Agents 39%
5. Population 36%
6. Stroke 33%
7. Retrospective Studies 33%
8. Confidence Intervals 30%
9. Glucagon-Like Peptide-1 Receptor 29%
10. Denosumab 28%
11. Sodium-Glucose Transporter 2 Inhibitors 27%
12. Symporters 25%
13. Incidence 22%
14. Sequence Analysis 20%
15. Safety 20%
16. Tumor Necrosis Factor Inhibitors 18%
17. Systematic Reviews 18%
18. Electronic Health Records 16%
19. Meta-Analysis 16%
20. 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol 16%
21. Propensity Score 16%
22. Therapeutics 15%
23. Korea 15%
24. empagliflozin 15%
25. Pharmaceutical Preparations 15%
26. Anticoagulants 14%
27. Mortality 14%
28. Sulpiride 14%
29. Observational Studies 14%
30. Elderly 13%
31. Dementia 13%
32. Randomized Controlled Trials 13%
33. Case-Control Studies 13%
34. Young Adult 13%
35. Valproic Acid 13%
36. Hospitalization 12%
37. aflibercept 12%
38. Risperidone 12%
39. Ranibizumab 11%
40. Drug-Related Side Effects and Adverse Reactions 11%
41. Proportional Hazards Models 11%
42. Haloperidol 11%